// App-Quantinova.ai

466 : Venetoclax and Navitoclax in Pediatric Patients with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Researchers

Presenter

  • Jeffrey E. Rubnitz

Principal Investigators

  • Thomas B. Alexander

  • Theodore W. Laetsch

  • Seong Lin Khaw

  • Vinod A. Pullarkat

  • Joseph T. Opferman

  • Kathryn G Roberts

  • Lindsey Rosenwinkel

  • Bo Tong

  • John C. Pesko

  • Mohamed Badawi

  • Deeksha Vishwamitra

  • Su Young Kim

  • Charles G Mullighan

  • Norman J. Lacayo

Medical Centers

  • Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN

  • Department of Nutrition, University of North Carolina, Chapel Hill, NC

  • Department of Pediatrics, The University of Texas Southwestern Medical Center/Children's Health, Dallas, TX

  • Royal Children's Hospital, Melbourne, Victoria, Australia

  • Department of Hematology and Hematopietic Cell Transplantation, City of Hope, Duarte, CA

  • Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN

  • Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN

  • AbbVie, Inc., North Chicago, IL

  • AbbVie, Inc., North Chicago, IL

  • Department of Pediatrics, Division of Hematology-Oncology, Stanford University, Palo Alto, CA

Locations

  • United States

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Lymphomas

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Asparaginase

  • Vincristine

  • Navitoclax

  • Venetoclax

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Dose Escalation

  • Cohort

Phase

  • I

Study Id's

  • NCT03181126

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved